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Abstract 
Background: Previous studies reported that 17β‑estradiol may influence the progression of diabetic renal disease 
in females. The present study was intended to provide an insight into the specific effects of progesterone, the other 
female sex hormone, in the diabetic renal complications.
Methods: Adult female wistar rats were divided into four groups (n = 6/group): intact control (non‑diabetic, ND), 
intact diabetic (D), ovariectomized diabetic (D‑OVX) and ovariectomized diabetic which were treated with proges‑
terone (D‑OVX + P; 10 mg/kg, s.c, every second day) for 10 weeks. Diabetes was induced by a single dose injection 
of 55 mg/kg streptozotocin. Expressions of transforming growth factor‑β (TGF‑β), fibronectin, vascular endothelial 
growth factor‑A (VEGF‑A), angiotensin II type 1 receptor (ATR1) and podocyte markers (nephrin and podocin) were 
assessed by immunohistochemistry and real‑time PCR.
Results: The treatment of D‑OVX rats with progesterone attenuated diabetic‑associated increases in the urinary 
albumin to creatinine ratio, glomerulosclerosi and the expression of profibrotic and angiogenic factors (TGF‑β, 
Fibronectin and VEGF‑A). Furthermore, progesterone supplementation prevented diabetes‑induced downregula‑
tion of nephrin and podocin while the overexpression of ATR1 in the diabetic rats was inhibited by the progesterone 
supplementation.
Conclusion: These results provided evidence, for the first time, that the replacement of progesterone can ameliorate 
the renal damage in the experimental models of diabetic nephropathy through improving the renal function; the 
inhibition of renal fibrosis and abnormal angiogenesis; along with the amelioration of podocyte injury. Additionally, 
the blocking of renin‑angiotensin system through the down‑regulation of ATR1 expression may also account for the 
reno‑protective effect of progesterone.
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Background
Among the diabetic complications, the diabetic nephrop-
athy (DN) is the single most common cause of end-stage 
renal failure worldwide, and a major indication for dialy-
sis and transplantation [1, 2]. DN is mainly caused by 
haemodynamic and structural changes including glo-
merular hyperfiltration and hypertrophy, thickening of 
glomerular basement membrane, expansion of mesangial 
extracellular matrix and fibrosis that is associated with 
decline of glomerular filtration rate and substantial pro-
teinuria [2]. In spite of the number of studies on human 
and rodent models of experimental DN, effective therapy 
is not available yet. Consequently, the search for drugs to 
blockade of the progression of DN has high priority in 
biomedical research.
Increasing evidence suggests that non-diabetic pre-
menopausal women have a lower incidence, prevalence, 
and progression of many renal diseases compared to 
age-matched non-diabetic men [3, 4]. These observa-
tions suggest that female gender may be protective, and 
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that male gender may be a risk factor for the develop-
ment and progression of non-diabetic renal disease [3, 
5]. However, insight from in  vitro studies and animal 
models suggest that diabetes is a state of an imbalance in 
sex steroids hormone levels [5]. Experimental and clini-
cal studies showed that this imbalance in sex hormone 
levels, decreased estradiol and increased testosterone, 
in female streptozotocin (STZ)-induced diabetic rats is 
associated with the progression of DN, which support the 
notion that sex hormones may play a role in the patho-
genesis of diabetic renal disease [5, 6]. Reduced levels of 
plasma estradiol and imbalance in the renal expression 
of estrogen receptors may explain why female gender is 
no longer a renoprotection factor in the setting of dia-
betes mellitus [7]. This hypothesis is in line with previ-
ous studies reporting that restoring estradiol levels in 
STZ-induced diabetic rats by 17β-estradiol replacement 
is renoprotective by attenuating the decline in renal func-
tion and pathology associated with DN [6, 8].
What remains unclear is the role that progesterone, 
the other female sex hormone, plays in the pathology of 
the DN. In thekidney, progesterone receptors have been 
found mainly in distal tubule cells, although they are 
present in cortex and medulla of males and females kid-
neys at the level of transcription and translation [5, 9]. 
In the ovariectomized rats with renal ablation, estradiol 
protected against proteinuria and glomerulsclerosis, but 
the rats treated with estradiol plus progesterone exhib-
ited the same renal damage as vehicle-treated rats [10]. 
These findings suggest that the presence of progesterone 
may attenuate the beneficial effects of estradiol in that 
experiment. However, in other studies, renal injuries of 
various etiologies were ameliorated by progesterone. The 
age-dependent decrease in the renal functional reserve 
and proximal tubular fluid output in the ovariectomized 
rats were prevented by estradiol alone or estradiol and 
progesterone [11]. Similarly, in ischemia–reperfusion–
induced acute kidney injury, the exogenous administra-
tion of progesterone exerts significant antioxidant and 
renoprotective effects in a dose-dependent manner [12]. 
Finally, in the DOCA salt hypertension rats, the treat-
ment with estrogen plus progesterone or progesterone, 
but not estrogen alone, attenuated renal damage [13].
Similar to estrogen, diabetic females also exhibit a 
decrease in progesterone levels [14]. However, no stud-
ies to date have addressed the effects of progesterone in 
DN. Therefore, the present study was intended to pro-
vide insight into the specific effects of progesterone in 
diabetic renal complications. We demonstrate that in the 
STZ-induced diabetic rat, replacement with progester-
one for 10  weeks is renoprotective, by improvement of 
renal functional and structural changes and inhibition of 
fibrosis.
Methods
Induction of diabetes and experimental protocols
All experimental procedures were pre-approved by the 
university animal care and use committee (Protocol 
number: 16/3/3/257). The study was performed in female 
adult Wister rats, 55–60 days old and weighing approxi-
mately 200 g. The rats were housed in a controlled envi-
ronment at 21–23 °C on an illumination schedule of 12 h 
of light and 12  h of darkness. Standard pellet food and 
water were provided ad libitum. All groups were feed the 
recommended diet for maintenance with 5 % total fat and 
18 % total protein.
Diabetes was induced in rats by intera-peritoneal 
injecting a freshly prepared STZ) Sigma-Aldrich, USA; 
55 mg/kg; dissolved in 0.1 M acetate buffer; pH 4.5) after 
an overnight fast. A control group of 6 rats received cit-
rate buffer only. The diabetic rats were ovariectomized 
two days after the STZ injection, once serum glucose is 
higher than 300 g/dl. The procedure for ovariectomy fol-
lowed the method of Khajuria et  al. [15]. The animals 
were anesthetized with a combination of ketamine/xyla-
zine anesthesia (100/10  mg/kg, i.p.). After the anesthe-
sia was confirmed, the area of surgery was cleaned with 
ethanol and a single ventral transverse incision (0.5 cm) 
was made through the skin and the bilateral ovaries and 
the ovarian fats were located. Then, ovaries were isolated 
by ligation of the most proximal portion of the oviduct 
before removal. The surgical incision was sutured and 
the animals were reversed to their cages to recover from 
surgery.
After that, the rats were randomly divided into four 
treatment groups (n  =  6 per group): (1) intact control 
(non-diabetic, ND), (2) intact diabetic (D), (3) ovariecto-
mized diabetic (D-OVX) and (4) ovariectomized diabetic 
which were treated with progesterone (D-OVX  +  P). 
Progesterone (10  mg/kg, Sigma-Aldrich, USA) was dis-
solved in sesame oil (Sigma-Aldrich, USA) and admin-
istered subcutaneously every second day for 10  weeks 
after induction of diabetes [10]. The ND, D and D-OVX 
groups were received the vehicle only. Rats were weighed 
every week and the dose of administration was adjusted 
according to recorded body weight.
Urine, blood and tissue collection
At the end of 10 weeks of treatment, the rats were placed 
in metabolic cages 1 day before sacrifice, and urine was 
collected for 24 h for the analysis of urine albumin con-
centration and the urine output. Then, the animals were 
weighed and anesthetized with ketamine and xylazine 
(100/10  mg/kg, i.p.), and blood samples were collected 
(via cardiac puncture). The right kidney was removed and 
then transferred into RNAlater solution (Sigma-Aldrich, 
USA) for the real time PCR analysis. The left kidney was 
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fixed with 4 % paraformaldehyde for morphological and 
immunohistochemical analysis. The animals were sacri-
ficed via anesthetic overdose.
Measurements of blood glucose, urinary albumin 
to creatinine ratio and serum progesterone levels
the blood glucose level was determined by glucometer 
(Accu-Chek Performa, Roche Diagnostics). Urine sam-
ples were centrifuged at 4  °C and 2000 rpm for 10 min. 
The urinary albumin and creatinine concentrations in the 
supernatant were measured using Albumin Rat ELISA kit 
(Abcam, UK) and creatinine ELISA kit (Cusabio, China) 
according to the manufacturer’s protocols. The urinary 
albumin to creatinine ratio (UACR) was calculated based 
on the albuminuria and urine creatinine level (albumin 
mg/creatinine g) [16]. Serum progesterone and estradiol 
levels were measured by commercially available ELISA 
kits (Biocheck, Inc. Foster City CA, USA and Cusabio, 
wuhan, China, respectively), according to the manufac-
turer’s protocols.
Estimation of glomerulosclerosis
After the fixation in 4  % paraformaldehyde, the tis-
sues were processed to paraffin, sectioned at 4  μm, and 
stained with periodic acid Schiff (PAS) using PAS stain 
Kit (Abcam, UK) according to the manufacturer’s pro-
tocols. One hundred glomeruli per section were ran-
domly selected and the PAS-stained sections were 
examined by observer masked to the treatment groups 
using the light microscope. The degree of glomerular 
damage was assessed using a semi-quantitative scoring 
method: grade 0, normal glomeruli; grade 1, sclerotic 
area up to 25  % (minimal sclerosis); grade 2, sclerotic 
area 25–50  % (moderate sclerosis); grade 3, sclerotic 
area 50–75 % (moderate-severe sclerosis); grade 4, scle-
rotic area 75–100  % (severe sclerosis). The glomerulo-
sclerotic index (GSI) was calculated using the following 
formula: GSI = (1 × n1) + (2 × n2) + (3 × n3) + (4 × n
4)/n0 + n1 + n2 + n3 + n4, where nx is the number of 
glomeruli in each grade of glomerulosclerosis [17].
RNA preparation and reverse transcription
Total RNA was extracted from RNAlater-preserved 
kidney tissues using an RNeasy mini tissue kit (Qia-
gen, USA) according to the manufacture protocols. The 
resulting RNA pellets were dissolved in RNase-free 
water and the quantity and quality of the isolated RNA 
were determined by absorbance at 260 and 280 nm and 
OD 260/280  nm ratios >1.8 were obtained for all sam-
ples, indicating high purity. Samples were then stored at 
−20 °C for subsequent RT-PCR analysis.
Total RNA (0.5  µg) was reversely transcribed using 
oligo-(dT)15 primer in a 20-µl reaction according to the 
manufacturer’s instructions (iNtRON Biotechnology, 
S.Korea). Reverse transcription reactions were carried 
out at 25 °C for 10 min followed by 42 °C for 60 min and 
95  °C for 5  min. The resulting first-strands cDNA were 
stored at −20 °C until use for real time RT-PCR.
Real time RT‑PCR
Quantitative real time RT-PCR was carried out on Line-
Gene 9600 Real-Time PCR system (Bioer Technology 
Co, Bingjiang, China), using β-actin as a non-regulated 
reference gene. Primers were designed and synthesized 
by IDT (Integrated DNA Technologies, INC., IA; Addi-
tional file  1: Table  S1). The SYBR-PCR reactions were 
performed using the KAPA SYBR® FAST Universal 2X 
qPCR master mix (KAPA Biosystem, USA) in 10 μl final 
volume. The amplification conditions for quantification 
were: 95 °C for 3 min and 45 cycles of 95 °C for 3 s and 
60  °C for 20 s. After the amplification efficiency of each 
target and reference gene was validated, the relative gene 
expression levels were determined by the ΔΔCT method 
as described by Livak and Schmittgen [18]. The levels of 
genes expression were expressed as the normalized ratio 
of gene expression relative to β-actin mRNA level using 
one sample from the control group as calibrator.
Immunohistochemistry
Immunohistochemical staining was performed with the 
ImmunoCruz Rabbit/Mouse ABC Staining System Kit 
(Santa Cruz, USA) according to the manufacture pro-
tocol. In brief, mounted sections were deparaffinized in 
xylene and rehydrated in descending series of alcohol 
concentrations. In order to expose the masked antigenic 
sites, sections were subjected to autoclave at 121  °C in 
citrate buffer (10 mM sodium citrate pH 6.0) for 10 min 
and allowed to cool at room temperature for 20 min. To 
quench endogenous peroxidase activity, sections were 
incubated in 1  % methanolic H2O2 for 20  min. Non-
specific binding sites were blocked with protein block 
for 30  min. Sections were then incubated with specific 
primary antibodies against: TGF-β (1:100; Santa Cruz/
USA; Cat.No.sc-146), Fibronectin (1:250; Abcam/UK; 
Cat.No.ab2413), matrix metalloproteinase-2 (MMP-2; 
1:100; Santa Cruz/USA; Cat.No. sc-13595), angiotensin 
II (Ang II) type I receptor (ATR1; 1:100; Santa Cruz/
USA; Cat.No.sc-1173), vascular endothelial growth 
factor-A (VEGF-A; 1:100; Santa Cruz/USA; Cat.No.sc-
7269) and podocyte markers (nephrin and podocin) 
proteins (1:100; Abcam/UK; Cat.No.ab183099 and Cat.
No.ab50339, respectively). For negative controls, the pri-
mary antibody was omitted. At the end of each primary 
antibody incubation period, the sections were washed 
three times with phosphate buffer saline (PBS) and sec-
tions were then incubated with biotinylated secondary 
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antibody for 30  min at room temperature in a humidi-
fied chamber. The sections were then washed three times 
with PBS and incubated with AB enzyme reagent for 
30  min at room temperature in a humidified chamber. 
The immunoreactions were developed by incubate the 
sections in 1–3 drops peroxidase substrate. The reaction 
was terminated in distilled water, and the sections were 
counterstained with Mayers haematoxylin, dehydrated 
and mounted.
Statistical analysis
All data will be expressed as mean  ±  SEM. One-way 
analysis of variance (ANOVA) was used to identify differ-
ences between groups. When this indicated significance 
(P < 0.05), Tukey post hoc test analysis was used to deter-
mine which conditions are significantly different from 
each other. All statistical analysis was performed using 
SPSS version 14.0 for Windows (SPSS Inc., Chicago, IL, 
USA).
Results
Metabolic and physiological parameters in control 
and diabetic rats
As shown in Table  1, after 10  weeks of diabetes blood 
glucose was significantly higher in the D than in the ND 
rats. A similar increase in blood glucose was observed in 
the diabetic group with OVX, and OVX + P supplemen-
tation. The diabetic rats showed a significant decrease 
in body weight (Additional file  2: Fig.  S1; P  <  0.05) as 
compared with the ND group. However, no differences 
in body weight were observed between the intact, the 
D-OVX, or the D-OVX + P in the diabetic groups. A sig-
nificantly increased level of UACR (Table 1; P < 0.05) was 
evident in the D group compared to the ND group, with 
the exacerbation in the D-OVX rats. The treatment of the 
diabetic rats with progesterone significantly recovered 
the UACR (Table 1; P < 0.05) in comparison with the D 
and the D-OVX groups, suggesting that the progesterone 
replacement attenuated the progression of the DN.
There was a trend toward lower serum progesterone 
and estrogen levels in the D group compared to the ND 
rats, but this difference was not statistically significant 
(Table 1; P > 0.10). However, there was a tendency for a 
higher serum progesterone level in the D-OVX + P com-
pared with the D group (Table 1; P < 0.10).
Effect of progesterone replacement on glomerular 
hypertrophy and early markers of fibrosis
At the end of 10  weeks of treatment, the diabetic rats 
with vehicle treatment showed a marked glomeru-
lar hypertrophy, a mesangial expansion and a clearly 
increased accumulation of extracellular matrix in the 
mesangium compared to ND. Consequently, the GSI 
of the D rats was significantly higher than ND controls 
(ND, 0.16 ± 0.08; D, 2.41 ± 0.57; P < 0.05; Fig. 1B). The 
D-OVX rats showed the highest GSI score while treat-
ment of the D-OVX rats with progesterone ameliorated 
the above pathogenic findings.
To determine the effect of progesterone on extracel-
lular matrix (ECM) proteins deposition in glomeruli, we 
analyzed the TGF-β and fibronectin expression in the 
in renal glomeruli in the diabetic kidney. As presented 
in Figs.  2A and 3A, the immunohistochemistry analysis 
demonstrated that diabetes was associated with an over-
all increase in the intensity of immunostaining for TGF-β 
and fibronectin in the D and D-OVX groups. Consist-
ent with the immunohistochemical findings, the levels 
of mRNA encoding for TGF-β and fibronectin were sig-
nificantly greater in the D and the D-OVX groups than 
in the ND group (Figs. 2B, 3B; P < 0.05). The treatment 
of D-OVX rats with progesterone decreased the over 
expression of these markers of fibrosis, suggesting that 
progesterone treatment inhibits the progression of renal 
fibrosis diabetic kidney.
It has been shown that the glucose-induced inhibi-
tion of matrix degrading enzymes such as MMP-2 is 
believed to contribute to accumulation of mesangial 
ECM proteins in the diabetic kidney [19]. Therefore, 
we determined whether the progesterone affects the 
expression of MMP-2 in the diabetic kidney or not. The 
results showed that the MMP-2 mRNA expression and 
the immunostaining intensity were decreased in the 
D and the D-OVX groups compared to the kidney of 
the ND group (Fig. 4A, B). The progesterone treatment 
did not affect significantly the MMP-2 mRNA levels in 
the diabetic kidney when compared to that in the ND 
control group (P > 0.05; Fig. 5B). However, the immu-
nohistochemistry analysis demonstrated that the pro-
gesterone treatment increased the protein expression 
of MMP-2; suggesting a possible post-transcriptional 
regulation of the MMP-2 protein by the progesterone 
treatment.
Table 1 Effects of progesterone supplementation on met-
abolic and renal parameters
Data represent the mean ± SEM. * P < 0.05 compared to the ND group. 
# P < 0.05 compared to D and OVX‑D groups. £ P < 0.10 compared to D group
UACR urinary albumin to creatinine ratio
ND D D‑OVX D‑OVX + P
Blood glucose, 
mg/dl
96.6 ± 4.8 454 ± 50.1* 476 ± 10.5* 481 ± 9.1*
Serum proges‑
terone, ng/ml
29.9 ± 2.2 25.9 ± 0.6 13.2 ± 3.3* 32.1 ± 3.9£
serum estro‑
gen, pg/ml
46.3 ± 2.9 40.2 ± 0.6 19.4 ± 0.09* 29.6 ± 3.4*
UACR, mg/g 20.5 ± 1.6 94.6 ± 12.9* 127.2 ± 25.8* 59.4 ± 12.9*,#
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Progesterone restores the expression of protein and mRNA 
of podocyte markers (nephrin and podocin) in rats with the 
DN
The expression intensity and the distribution pattern 
of nephrin and podocin in glomeruli were observed by 
immunohistochemical staining (Figs. 5A, 6A). The stain-
ing of nephrin and podocin was prominent in the glo-
merular tufts in the ND rats. By contrast, in the D rats, 
the expression of nephrin and podocin was significantly 
decreased. This diabetes-associated decrease in the 
apparent intensity of the immunostaining of nephrin and 
podocin was exaggerated in the D-OVX group. Consist-
ent with the expression intensity of nephrin and podocin, 
the expression levels of nephrin and podocin mRNA were 
significantly decreased in the kidney of the untreated D 
and D-OVX rats compared with the ND rats (Figs.  5B, 
6B, P  <  0.05). However, the progesterone replacement 
partially (nephrin) or fully (podocin) improved the 
immunohistochemical staining intensity and the mRNA 
expression of podocyte markers in the D-OVX + P group 
compared with the D and the D-OVX rats.
Decreased ATR1 expression in the diabetic kidney 
by progesterone treatment
ATR1 overexpression plays an important role in the 
development and progression of the DN [20, 21]. Thus, 
we examined whether progesterone may protect against 
the renal injury via its effects on ATR1 protein and 
Fig. 1 Periodic acid‑Schiff (PAS) stained sections detect that progesterone replacement attenuated the glomerulosclerotic index (GSI) in the 
diabetic kidney. A PAS‑stained sections (magnification, ×200) show that the percentage of the PAS‑positive material, indicative of increased fibrosis, 
was significantly increased in the D and the D‑OVX groups compared with the ND group (arrows). Progesterone replacement inhibited the increase 
in the PAS‑positive material in the D + OVX + P group (B) GSI. Data represent the mean ± SEM. Means with different superscript letters are signifi‑
cantly different from one another (P < 0.05)
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mRNA expression. The real-time PCR and immunohisto-
chemistry showed that the ATR1 mRNA and the protein 
expression levels were high in both the D and the D-OVX 
rats comapred with the ND rats, and these changes were 
significantly attenuated by the progesterone replacment 
(Fig. 7A, B, P < 0.05).
Progesterone modulated angiogenesis in the DN
Previous studies demonstrated a significant increase in 
VEGF-A mRNA expressions, an important growth fac-
tor for vascular development and angiogenesis, in the 
kidney of STZ-diabetic rats [22]. Therefore, we exam-
ined whether progesterone could influence the of kid-
neys expression level of VEGF-A in the diabetic rats. 
Figure 8A, B, shows that the mRNA expression and the 
protein levels of VEGF-A were significantly increased in 
the D and the D-OVX rats compared with the ND rats. 
The treatment with progesterone resulted in a marked 
reduction of the VEGF-A levels in the D-OVX + P rats as 
compared with the D and the D-OVX rats.
Disscusion
Increasing evidence suggests that sex hormones (estra-
diol and dihydrotestosterone) are important regulators 
of the renal function and may be novel targets for the 
treatment and prevention of the diabetic renal disease 
in females and males, respectively [8, 23]. So far, the role 
that progesterone, the other female sex hormone, plays 
during the DN progression is still unclear. Therefore, 
the present study was intended to provide an insight 
into the specific effects of progesterone in diabetic renal 
complications. We demonstrate that in the STZ-induced 
Fig. 2 Immunohistochemistry and real‑time PCR detect that progesterone replacement inhibits the TGF‑β expression in the diabetic kidney. A 
immunohistochemical stain of the kidney sections (hematoxylin staining; magnification, ×400) show that the TGF‑β immunostaining (brown 
staining) in the glomeruli was much stronger in the D and the D‑OVX groups compared with the ND group (arrows). Progesterone replacement 
inhibited the increase in the TGF‑β immunostaining in the D + OVX + P group. B TGF‑β mRNA expression by real‑time PCR. Data represent the 
mean ± SEM. Means with different superscript letters are significantly different from one another (P < 0.05)
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diabetic ovariectomized rat, the replacement with pro-
gesterone for 10 weeks is renoprotective as evident from 
the restoration of various parameters as compared with 
the D and the D-OVX groups. In the present study, the 
administration of progesterone to the D-OVX rats sig-
nificantly reduced UACR, glomerulosclerosis, the expres-
sion of profibrotic factors (TGF-β and fibronectin) and 
the expression of angiogenesis-associated factor (VEGF). 
Moreover, the progesterone replacement retains the 
expressions of podocyte markers (nephrin and podocin) 
and decreased ATR1 expression in the diabetic kidney.
The present work revealed that the treatment with pro-
gesterone could reduce the early manifestations of the 
DN as shown by a significant reduction of UACR, a key 
measure of the renal function [16], at 10 weeks after dia-
betes in treated diabetic animals compared with controls. 
A similar effect of progesterone on proteinuria has been 
observed in the ischemia–reperfusion–induced acute 
kidney injury [12]. The renal podocyte foot processes 
and associated slit diaphragms ensure the integrity of the 
renal basement membrane that forms the barrier to uri-
nary protein loss [24]. To clarify the mechanisms of the 
beneficial effect of progesterone on proteinuria, we tested 
whether the progesterone replacement prevents down-
regulation of proteins required for slit diaphragm integ-
rity, podocin and nephrin. After 10  weeks of diabetes, 
the development of albuminuria in the diabetic rats was 
associated with decreases in podocyte abundance and 
distribution which was manifested by reduced mRNA 
and protein expression of nephrin and podocin in dia-
betic animals. Our data indicated that treatment with 
progesterone restored mRNA expression and staining 
Fig. 3 Immunohistochemistry and real‑time PCR detect that progesterone replacement inhibits the fibronectin expression in the diabetic kidney. A 
immunohistochemical stain of the kidney sections (hematoxylin staining; magnification, ×400) show that the fibronectin immunostaining (brown 
staining) in the glomeruli was much stronger in the D and the D‑OVX groups compared with the ND group (arrows). Progesterone replacement 
inhibited the increase in the fibronectin immunostaining in the D + OVX + P group. B fibronectin mRNA expression by real‑time PCR. Data repre‑
sent the mean ± SEM. Means with different superscript letters are significantly different from one another (P < 0.05)
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intensity of nephrin and podocin, suggesting a protective 
effect on the structure of podocytes. Hence, our data sug-
gest that the effects of progesterone on attenuating pro-
teinuria are possibly mediated by preventing the damage 
of podocytes in the diabetic conditions.
The expansion of the mesangial matrix and thicken-
ing of the glomerular basement membrane are the typi-
cal early presentation of DN [24]; and the current study 
confirms these findings. Both the glomerulosclerosis and 
tubulointerstitial fibrosis are characterized by the accu-
mulation of ECM proteins as a result of the increased 
synthesis and/or the reduced degradative rates of ECM 
proteins [25]. In the diabetic kidneys, the overexpression 
of TGF-β is believed to be the most potent stimulator 
of ECM proteins accumulation [26]. Our results show 
that the renal TGF-β1 expression levels were higher 
in STZ-diabetic rats relative to the normal rats and the 
progesterone treatment attenuated this increase (Fig. 2). 
In addition, we have demonstrated that fibronectin, an 
important constituent of ECM proteins, was induced in 
the diabetic rats and the upregulation of tissue fibronec-
tin in the diabetic kidney is effectively reversed after the 
progesterone treatment. Moreover, we observed that the 
progesterone treatment effectively increased the MMP-2 
protein but not the mRNA levels in the diabetic kidney, 
indicating a posttranscriptional regulation of MMP-2 by 
the progesterone replacement. In this context, it has been 
shown that various exogenous and endogenous factors 
Fig. 4 Immunohistochemistry and real‑time PCR detect that progesterone replacement increase the MMP‑2 protein, but not the mRNA levels in 
the diabetic kidney. A Immunohistochemical stain of the kidney sections (hematoxylin staining; magnification, ×400) show that the MMP‑2 immu‑
nostaining (brown staining) in the glomeruli was much stronger in the ND group compared with the D and the D‑OVX groups (arrows). Progester‑
one replacement inhibited the decrease in the MMP‑2 immunostaining in the D + OVX + P group. B MMP‑2 mRNA expressions by real‑time PCR. 
Data represent the mean ± SEM. Means with different superscript letters are significantly different from one another (P < 0.05)
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may regulate MMPs at the post-transcriptional level by 
stabilizing and/or destabilizing mRNA transcripts [27]. 
Taken together, the decrease in the expression of TGF-
β1 and fibronectin in the diabetic kidney by the proges-
terone treatment, as well as the increase in the MMP-2 
protein level clearly suggests that progesterone protects 
the development of renal fibrosis and glomerular mesan-
gial matrix accumulation associated with the DN, at least 
in part, by inhibiting the ECM proteins production and 
enhancing the ECM proteins degradation.
Numerous studies revealed that in the hibition of intra-
renal renin-angiotensin system (RAS) by using the angi-
otensin-converting enzyme inhibitors and/or the ATR1 
blockers can attenuate progressive glomerulosclerosis 
in renal disease models and can slow the progression of 
renal disease in patients with type 2 diabetes [28]. Inde-
pendent of its hemodynamic action, the exposure of 
mesangial cells to Ang II results in stimulation of TGF-β 
expression and secretion which leads to the increased 
synthesis and the decreased degradation of ECM pro-
teins [28]. These data support the notion that Ang II can 
worsen the DN. The effects of Ang II are mediated by two 
plasma membrane Ang II receptors (ATR1 and ATR2). 
Most of the known effects of Ang II in adult tissues are 
attributable to the ATR1 [29]. Therefore, in this study we 
investigate the role of progesterone in the ATR1 expres-
sion in the kidney under diabetic conditions. Consistent 
with previous studies [21, 30], the present study found 
that ATR1 mRNA and protein expression levels were 
upregulated in the diabetic kidney, suggesting a potential 
Fig. 5 Immunohistochemistry and real‑time PCR detect that progesterone replacement partially restores the nephrin expression in the diabetic 
kidney. A immunohistochemical stain of the kidney sections (hematoxylin staining; magnification, ×400) show that the nephrin immunostain‑
ing (brown staining) in the glomeruli was much stronger in the ND group compared with the D and the D‑OVX groups (arrows). Progesterone 
replacement inhibited the decrease in the nephrin immunostaining in the D + OVX + P group. B nephrin mRNA expressions by real‑time PCR. Data 
represent the mean ± SEM. Means with different superscript letters are significantly different from one another (P < 0.05)
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role for ATR1 in the development and progression of 
renal injury secondary to diabetes mellitus. Because the 
progesterone replacement significantly reversed the 
upregulation of ATR1 in the diabetic kidney, we postu-
lated that the renal protective actions of progesterone 
may be related, at least in part, to the decrease in the sus-
ceptibility of diabetic kidney to the available circulating 
and locally produced Ang II, and hence blocks the local 
activation of RAS. Certainly, this hypothesis needs to be 
tested by further studies.
There is a growing body of studies showing that angio-
genesis may play an important role in the pathogenesis 
of the DN. Angiogenesis is associated with glomerular 
hypertrophy and urinary albumin excretion in the DN 
[31]. Additionally, previous studies have indicated that 
blocking angiogenesis attenuated the glomerular base-
ment membrane thickening, the mesangial expansion, 
and the TGF-β expression in diabetic animals [31, 32]. 
The angiogenic growth factor VEGF-A is induced by 
high glucose levels in the early phases of diabetes, lead-
ing to the development of early features of the DN [31, 
33]. In the present study, the level of VEGF-A was mark-
edly increased in the kidney of the diabetic rats, which 
is consistent with previous studies [2, 33]. We demon-
strated also for the first time that progesterone could 
attenuate the DN via inhibiting the angiogenesis-associ-
ated factor VEGF-A. These findings suggest that block-
ing the angiogenesis induced by VEGF-A may play an 
Fig. 6 Immunohistochemistry and real‑time PCR detect that progesterone replacement restores the podocin expression in the diabetic kidney. A 
Immunohistochemical stain of the kidney sections (hematoxylin staining; magnification, ×400) show that the podocin immunostaining (brown 
staining) in the glomeruli was much stronger in the ND group compared with the D and the D‑OVX groups (arrows). Progesterone replacement 
inhibited the decrease in the podocin immunostaining in the D + OVX + P group. B Podocin mRNA expressions by real‑time PCR. Data represent 
the mean ± SEM. Means with different superscript letters are significantly different from one another (P < 0.05)
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important role in the renal benefit of progesterone in the 
diabetic rats.
Progression of diabetic renal disease in STZ-diabetic 
male rats has been reported by some authors to be cor-
related with the lower ratio of testosterone to oestra-
diol or progesterone rather than with absolute levels of 
sex hormones [34]. In the present work we measured 
the concentrations of progesterone and estrogen with-
out testosterone. However, given the fact that experi-
mental diabetes leads to increased plasma testosterone 
levels in the adult female rat [3, 35], mainly from adre-
nal origin [35], we speculated that increase rather 
than decrease in the ratio of testosterone to oestra-
diol or progesterone is correlated with the severity of 
the diabetic renal disease in the female STZ-induced 
diabetic rat. Further studies are warranted to examine 
the effects of testosterone in the pathophysiology of 
the diabetic renal disease in a female animal model of 
diabetes.
Finally, many hormonal abnormalities and sexual dys-
functions which occur in women with diabetes may be 
treated with progesterone alone or estrogen-progester-
one combinations [36, 37]. Although our report is an 
experimental study of DN in the rat, we provide a proof 
of concept evidence that progesterone may be effective 
in controlling both the sexual dysfunction and the DN in 
the diabetic women.
In conclusion, our study is the first to demonstrate 
that the progesterone replacement can ameliorate renal 
damage in experimental models of the DN through 
improving the renal function; inhibition of renal fibrosis 
and angiogenesis; along with amelioration of podocyte 
Fig. 7 Immunohistochemistry and real‑time PCR detect that progesterone replacement inhibits the AT1R expression in the diabetic kidney. A 
Immunohistochemical stain of the kidney sections (hematoxylin staining; magnification, ×400) show that the AT1R immunostaining (brown 
staining) in the glomeruli was much stronger in the D and the D‑OVX groups compared with the ND group (arrows). Progesterone replacement 
inhibited the increase in the AT1R immunostaining in the D + OVX + P group. B AT1R mRNA expression by real‑time PCR. Data represent the 
mean ± SEM. Means with different superscript letters are significantly different from one another (P < 0.05)
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injury. We demonstrated also that progesterone could 
decrease the Ang II effect in the DN through decrease 
the ATR1 expression. These findings suggest that pro-
gesterone replacement may have a therapeutic potential 
in the DN.
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